Hansoh Pharma FY25 profit climbs 27.1% to RMB 5.6 billion; revenue rises 22.6% to RMB 15 billion

Reuters03-29
Hansoh Pharma FY25 profit climbs 27.1% to RMB 5.6 billion; revenue rises 22.6% to RMB 15 billion
  • Hansoh Pharma FY25 profit for the year climbed 27.1% to RMB 5.6 billion.
  • Revenue rose 22.6% to RMB 15 billion.
  • Basic earnings per share increased 26.4% to RMB 0.93.
  • Innovative medicines and collaborative products revenue jumped 30.4% to RMB 12.4 billion, lifting mix to 82.2% of revenue.
  • Board recommended final dividend of HK$0.20 per share; full-year dividend totaled HK$0.43 per share.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on March 29, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment